[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360316-105":59,"doc-detail-360316-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-outcomes-of-ivosidenib-in-idh1-mutant-biliary-tract-cancer-a-multicenter-retrospective-analysis-and-comparison-with-the-trinetx-database","Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer - A Multicenter Retrospective Analysis and Comparison with the TrinetX Database","","Real-world outcomes for ivosidenib in IDH1-mutant biliary tract cancer are assessed because phase III evidence from ClarIDHy does not fully capture everyday clinical practice. This multicenter retrospective analysis evaluates efficacy and safety in patients treated at four German university hospitals (2020-2024) and compares clinical outcomes with a TriNetX cohort. Fourteen treated patients were identified, with reported response patterns, progression-free survival, and overall survival, alongside toxicity and discontinuation observations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-outcomes-of-ivosidenib-in-idh1-mutant-biliary-tract-cancer-a-multicenter-retrospective-analysis-and-comparison-with-the-trinetx-database/360316/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-outcomes-of-ivosidenib-in-idh1-mutant-biliary-tract-cancer-a-multicenter-retrospective-analysis-and-comparison-with-the-trinetx-database/360316.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is ivosidenib studied for IDH1-mutant biliary tract cancer beyond the ClarIDHy trial?","Question",{"text":112,"@type":113},"The background notes that phase III results establish targeted therapy, but real-world efficacy and safety data in broader cohorts remain limited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and how were external outcomes obtained?",{"text":117,"@type":113},"Patients receiving ivosidenib for IDH1-mutant biliary tract cancer were retrospectively identified from four German university centers (2020-2024). Outcomes were also retrieved from the TriNetX global health network database.",{"name":119,"@type":110,"acceptedAnswer":120},"What key clinical outcomes were reported in the retrospective cohort and the TriNetX comparison?",{"text":121,"@type":113},"In the cohort, partial response and stable disease occurred in a subset, with median progression-free survival reported as 5.6 months and median overall survival as 12.7 months. The TriNetX cohort included 228 patients with median overall survival reported as 9.6 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360316,1791067658,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Targeted Oncology (2026) 21:411–420  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01211-6  \nReal‑World Outcomes of Ivosidenib in IDH1‑Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database  \nLena Dreikhausen1 · Alexander Olkus2,3,4 · Michael Dill2,3,4 · Christoph Springfeld5 · Philipp Heumann6 · Nadine Schulte1 · Konstantina Atanasova1 · Matthias P. Ebert1,7,8,9 · Anne Letsch10,11 · Anna M. Wandmacher10,11,12 · Tianzuo Zhan1,7,8,9  \nReceived: 12 November 2025 / Accepted: 30 March 2026 / Published online: 20 April 2026 © The Author(s) 2026  \nAbstract  \nBackground Ivosidenib is established as targeted therapy in patients with isocitrate dehydrogenase 1 (IDH1)-mutant advanced biliary tract cancer based on results of the phase III ClarIDHy trial. However, data on the efficacy of ivosidenib in real-world cohorts are limited.  \nObjective This retrospective analysis aims to provide data on the efficacy and safety of ivosidenib in biliary tract cancer ina real-world cohort.  \nMethods Patients with IDH1 mutant biliary tract cancer treated with ivosidenib at four German university medical centers from 2020 to 2024 were retrospectively identified. Clinicopathological parameters and treatment courses were collected. Furthermore, clinical outcomes of patients with biliary tract cancer who received ivosidenib were retrospectively retrieved from the global health network database TriNetX.  \nResults In total, 14 patients who received ivosidenib were identified. Mean age at diagnosis was 61 years and 50% of patients were female. Nine patients had an IDH1 R132C, four an IHD1 R132L, and one an IDH1 R132S mutation. Ten patients received ivosidenib as second-line therapy and four in later lines. Partial response was observed in two patients, stable disease in three, and progressive disease in nine patients. Median progression-free survival was 5.6 months (95% confidence interval 4. 3, not estimated) and median overall survival was 12.7 months (95% confidence interval 8.2, not estimated) . No discontinuation of ivosidenib because of toxicity was observed. A total of 228 patients were identified in the TriNetX database. Mean age was 64.4 years and 64% of patients were female. Median overall survival in this cohort was 9.6 months (95% confidence interval 8.07, 11. 19) .  \nConclusions Real-world data from our cohort and the TriNetX database support the oncological outcomes reported in the ClarIDHy trial and other real-world cohorts.  \n1 Introduction  \nBiliary tract cancer (BTC) is a rare disease with an unfavorable prognosis and limited therapeutic options in advanced stages of the disease. Seventy percent of patients present with locally advanced or metastatic disease at the time of diagnosis, without the possibility for curative resection [1] . Even after surgical resection, more than half of patients experience disease recurrence [2 , 3] . Five-year survival rates range between 7 and 20%, underlining the need for more effective treatment strategies [4] . In non-resectable disease, chemotherapy combined with immunotherapy has become standard as first-line therapy since 2022, based on the results of the TOPAZ-1 trial [5] .  \nHowever, in further therapy lines, treatment options are limited. Immunohistochemical staining to detect mismatch repair deficiency and overexpression of the human epidermal growth factor receptor 2 receptor is recommended as well as tumor genome sequencing to detect potentially actionable mutations [6] .  \nThe mutational landscape of BTC is heterogeneous and depends on the location of the disease. However, up to 60% of BTC harbor potentially actionable genetic alterations [7] . Recently, new targeted therapeutic strategies have been introduced and in part been integrated in therapeutic management of these patients [8], including pemigatinib or futibatinib for BTC with FGFR2 fusions or rearrangements [9] or dabrafinib plus trametinib for BRAFV600E mutant BT","cbCaim7KhB9HhbKO","https://ap.wps.com/l/cbCaim7KhB9HhbKO","pdf",871946,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is ivosidenib studied for IDH1-mutant biliary tract cancer beyond the ClarIDHy trial?\",\"answer\":\"The background notes that phase III results establish targeted therapy, but real-world efficacy and safety data in broader cohorts remain limited.\"},{\"question\":\"How were patients selected and how were external outcomes obtained?\",\"answer\":\"Patients receiving ivosidenib for IDH1-mutant biliary tract cancer were retrospectively identified from four German university centers (2020-2024). Outcomes were also retrieved from the TriNetX global health network database.\"},{\"question\":\"What key clinical outcomes were reported in the retrospective cohort and the TriNetX comparison?\",\"answer\":\"In the cohort, partial response and stable disease occurred in a subset, with median progression-free survival reported as 5.6 months and median overall survival as 12.7 months. The TriNetX cohort included 228 patients with median overall survival reported as 9.6 months.\"}]","Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer - A Multicenter Retrospective Analysis and Comparison with the TrinetX Database | PDF",1790139584,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9235f2b3c47bb1803448f68ff57cb607.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b75efaa08262c9f34849e216fb87a575.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fdfc071a3e6278dfca6c169e405ba87.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7af570966768474d0c0ba2a310121ef9.webp",980,1301]